ClinicalTrials.Veeva

Menu

Study to Assess the Prognostic Value of the Antithrombin III in the Acute Pancreatitis (AT-PROPANC)

F

Francisco Javier García Borobia

Status

Unknown

Conditions

Acute Pancreatitis

Study type

Observational

Funder types

Other

Identifiers

NCT02373293
GAR-BOR/TAULI-2013

Details and patient eligibility

About

This is an epidemiological, observational, prospective, multicentric study in 400 adult patients admitted to hospital for mild acute pancreatitis to to assess the prognostic value of the antithrombin III in the development of moderate or severe acute pancreatitis.

Full description

This is an epidemiological, observational, prospective, multicentric study in 400 adult patients admitted to hospital for mild acute pancreatitis to to assess the prognostic value of the antithrombin III in the development of moderate or severe acute pancreatitis.

In the context of clinical practice of general surgery and apparatus digestive services, patients entering with mild acute pancreatitis will be asked to participate in the study and if so, they will sign the informed consent.

On admission, demographic and anthropometric data of the patient will be recorded, as well as medical history, patient's admission data and vital signs. Patient's blood will be drawn for analysys and the risk of organ failure will be measured by modified Marshall and Apache II scales. The assessments and procedures performed are the standard practice at the center.

At 24 hours (± 3 hours) and at 7 days (or nine days to avoid weekends) after admisison, vital signs will be recorded, laboratory tests will be performed and the risk of organ failure will be measured by modified Marshall and Apache II scales.

At discharge of the patient (regardless of when it occurs), the outcome of the acute pancreatitis will be recorded.

. Those patients discharged within the first month after admission will be visited or called (according to standard practice at the center) one month after arrival, to record follow-up data, including health condition, readmissions and abdominal pain evaluation by visual analog scale.

Enrollment

400 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients diagnosed with mild acute pancreatitis according to seriousness criteria established by Banks et al, 2013.
  • Patients of either sex aged ≥ 18 years .
  • Patients who have given their written informed consent

Exclusion criteria

  • Patients with exacerbated chronic pancreatitis.
  • Patients with coagulation disorders (congenital and acquired antithrombin deficiency) .
  • Patients with liver cirrhosis.
  • Pregnant patients

Trial contacts and locations

2

Loading...

Central trial contact

Francisco Javier García Borobia, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems